Clinical Trial: The Value of Serum MicroRNA-21-5p and LncRNAgadd7 Expression Levels in Predicting the Severity and Prognosis of ARDS ( Acute Respiratory Distress Syndrome )

U.S., Feb. 14 -- ClinicalTrials.gov registry received information related to the study (NCT06825754) titled 'The Value of Serum MicroRNA-21-5p and LncRNAgadd7 Expression Levels in Predicting the Severity and Prognosis of ARDS ( Acute Respiratory Distress Syndrome )' on Feb. 07.

Brief Summary: By measuring the expression levels of MicroRNA-21-5p (miR-21-5p) and LncRNAgadd7 in the peripheral blood of ARDS patients, the study aims to explore the correlation between these levels and the severity and prognosis of ARDS.

Study Start Date: Nov. 01, 2023

Study Type: OBSERVATIONAL

Condition: Acute Respiratory Distress Syndrome

Recruitment Status: COMPLETED

Sponsor: Shao Yuekai

Information provided by (Responsible Party): Shao Yuekai, Zunyi Me...